Instead of just killing off cancer cells directly, chemotherapy works because it prompts the body's own defenses to destroy tumor cells, new research in mice suggests.
The findings, published April 4 in the journal Immunity, suggest the immune system plays a critical role in fighting cancer.
"You need the host immune system — the reaction against the tumor — to work," said study co-author Guido Kroemer, an immunologist at the National Institute of Health and Medical Research in France.
If follow-up studies in people show a similar effect, doctors could boost the immune response to increase chemotherapy's effectiveness or measure a patient's immune response to specific drugs to predict chemotherapy's success, Kroemer told LiveScience.
Until now, scientists had a limited understanding of how chemotherapy works. They assumed that the treatment worked by selectivelykilling more tumor cells than healthy cells, Kroemer said.
But the immune system also seemed to play a role. For instance, past work showed that chemotherapy required a particular immune cell type — called T-lymphocytes, or T-cells — in order to work against breast cancer.
To understand how T-lymphocytes identified tumor cells, Kroemer and his colleagues marked cancer cells in mice with a protein that glowed green. They then watched what happened to those cells after they gave the mice an anthracycline, a specific type of chemotherapy. Anthracyclines are used to treat breast cancer, as well as prostate and lung cancer.
The researchers found that specific immune cells were drawn to a chemical signal from the tumor cells and then presented them to the T-lymphocyte immune cells.
To show that this cell played a key role in chemo's effectiveness, the team showed that mice lacking these presenting molecules had a marked reduction in chemotherapy response.
The research suggests that the immune system may play a wider role in fighting cancer than previously thought, Kroemer said.